We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

124 hedge funds and large institutions have $1.25B invested in Heron Therapeutics in 2017 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 29 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

330% more call options, than puts

Call options by funds: $14.3M | Put options by funds: $3.32M

222% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 9

66% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 29

22% more capital invested

Capital invested by funds: $1.02B → $1.25B (+$224M)

19% more funds holding

Funds holding: 104 → 124 (+20)

9.97% less ownership

Funds ownership: 117.12% → 107.15% (-10%)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

Holders
124
Holders Change
+20
Holders Change %
+19.23%
% of All Funds
2.81%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.11%
New
29
Increased
48
Reduced
29
Closed
9
Calls
$14.3M
Puts
$3.32M
Net Calls
+$10.9M
Net Calls Change
+$387K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$24.6M
2
Citadel Advisors
Citadel Advisors
Florida
+$22.9M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$21.1M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$9.22M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$7.96M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$23.3M
2
CC
Carlson Capital
Texas
-$7.69M
3
CAM
Cormorant Asset Management
Massachusetts
-$6.03M
4
PA
Perceptive Advisors
New York
-$5.33M
5
KCM
Kingdon Capital Management
New York
-$4.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
26
Panagora Asset Management
Massachusetts
$6.5M -$189K -11,604 -3%
Millennium Management
27
Millennium Management
New York
$5.71M -$892K -54,701 -15%
JP Morgan Chase
28
JP Morgan Chase
New York
$5.16M +$4.61M +283,000 +12,817%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$4.7M -$1.23M -75,545 -23%
RSCM
30
Rock Springs Capital Management
Maryland
$4.53M +$4.08M +250,000 New
Charles Schwab
31
Charles Schwab
California
$4.4M +$1.33M +81,735 +51%
CIP
32
Chartwell Investment Partners
Pennsylvania
$3.66M +$930K +57,030 +39%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$3.63M -$53.7K -3,296 -2%
CAM
34
Cormorant Asset Management
Massachusetts
$3.62M -$6.03M -370,000 -65%
MIM
35
Monashee Investment Management
Massachusetts
$3.62M – – –
Mirae Asset Global Investments
36
Mirae Asset Global Investments
South Korea
$3.27M +$2.94M +180,600 New
Goldman Sachs
37
Goldman Sachs
New York
$2.64M -$2.12M -130,031 -47%
Morgan Stanley
38
Morgan Stanley
New York
$2.51M +$1.09M +66,633 +92%
CWG
39
C WorldWide Group
Denmark
$2.38M +$515K +31,600 +32%
Fisher Asset Management
40
Fisher Asset Management
Washington
$2.19M +$338K +20,705 +21%
DAM
41
Deltec Asset Management
New York
$2.12M +$1.91M +117,000 New
CM
42
Crestline Management
Texas
$2.1M +$1.24M +76,212 +190%
TCIM
43
TIAA CREF Investment Management
New York
$2.04M -$168K -10,291 -8%
Squarepoint
44
Squarepoint
New York
$2.02M +$1.26M +76,974 +222%
AllianceBernstein
45
AllianceBernstein
Tennessee
$2.01M +$735K +45,100 +69%
Allianz Asset Management
46
Allianz Asset Management
Germany
$1.98M -$1.91K -117 -0.1%
ACM
47
Asymmetry Capital Management
California
$1.79M +$591K +36,219 +58%
Swiss National Bank
48
Swiss National Bank
Switzerland
$1.78M +$326K +20,000 +25%
BRWA
49
B. Riley Wealth Advisors
Florida
$1.66M +$380K +23,310 +34%
SCA
50
Secor Capital Advisors
New York
$1.63M +$1.47M +90,099 New
1
2
3 4 5

HRTX Hedge Fund Activity: Q4 2017 in Review

124 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2017, worth a combined $1.25B — up 22% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new HRTX positions and 9 closed out — a net gain of 20 holders — while 48 added to existing stakes and 29 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $24.6M. The largest seller was Broadfin Capital, cutting an estimated $23.3M.

  • 124 institutional investors held Heron Therapeutics (HRTX) as of Q4 2017, up from 104 in Q3 2017.
  • Funds reported $1.25B of Heron Therapeutics stock for Q4 2017, up 22% quarter-over-quarter.
  • 29 funds opened new Heron Therapeutics positions in Q4 2017 and 9 closed out, a net change of +20 holders.
  • The largest Heron Therapeutics buyer in Q4 2017 was Fidelity Investments, an estimated $24.6M added.
  • The largest Heron Therapeutics seller in Q4 2017 was Broadfin Capital, an estimated $23.3M sold.

Based on aggregated 13F filings for Q4 2017.